Cytokinetics Inc (NAS:CYTK)
$ 48.98 -10.25 (-17.31%) Market Cap: 5.14 Bil Enterprise Value: 6.35 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 43/100

Cytokinetics Inc at Jefferies Healthcare Conference Transcript

Jun 08, 2023 / 01:30PM GMT
Release Date Price: $38.06 (-1.73%)
Akash Tewari
Jefferies - Analyst

Good morning, everyone. Day two of our healthcare conference. I hope everyone's enjoying it. For those who don't know me, my name is Akash Tewari. I'm a pharma and biotech analyst here at Jefferies. And I have the pleasure of hosting the Cytokinetics management team. This is one of our topics as an analyst. But maybe Robert, I'll hand it off to you for some brief introductory comments and we'll get into Q&A.

Robert Blum
Cytokinetics, Incorporated. - President & CEO

Sure. So I'm Robert Blum, I'm the President and CEO of Cytokinetics. I'm joined by Andrew Carlos, who's our Chief Commercial Officer today.

And before we get into the Q&A, I'll just provide a high-level summary of what this year has in store for us. It has the makings of being a transformational year for the company as we're expecting readout of results from the pivotal clinical trial of aficamten, our next-in-class cardiac myosin inhibitors. It's the subject of a Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot